NIH Clinical Center

This file is provided for reference purposes only. It was current when it was produced, but it is no longer maintained and may now be out of date. Persons with disabilities having difficulty accessing information may contact us for assistance. For reliable, current information on this and other health topics, we recommend consulting the NIH Clinical Center at http://www.cc.nih.gov/.

National Institutes of Health Clinical CenterProfile

Skip left navigation list link group.Contents

Introduction

Message from the Director

Important Events in Clinical Center History

Governance and Accreditation

Organization Structure and Programs

Heralding Fifty Years of Clinical Caring and Clinical Research

The Mark O. Hatfield Clinical Research Center

Activation Planning for the Clinical Research Center

The Edmond J. Safra Family Lodge

Clinical Research

Clinician Highlight

Clinical Research Training

Organizational Effectiveness and Efficiency

Public Outreach  End of left navigation list link group.

Introduction
Organizational Structure and Programs

Protocols by Research Type
(Onsite Intramural Protocols) Fiscal Year 2003

Clinical studies are medical research studies in which people participate as volunteers. Clinical research studies are a means of developing new treatments and medications for diseases and conditions. Natural history studies investigate normal human biology and disease development. Screening studies determine if individuals may be suitable candidates for inclusion in a particular study. Training studies provide an opportunity for staff physicians and other healthcare professionals to follow particular types of patients.

Chart: Total Active Protocols 1,239; Clinical Trials 535; Training: 33; Screening: 49; Natural History: 622.


Breakdown of Clinical Trials
(Onsite Intramural Protocols) Fiscal Year 2003

Chart: Total Clinical Trials 535: Phase I: 179; Phase II: 298; Phase III: 38; Phase IV: 20.

Clinical Trials Proceed Through Four Phases

Phase I:
Researchers test a new drug or treatment in a small group of people (20–80) for the first time to evaluate its safety, determine a safe dosage range and identify side effects.

Phase II:
The study drug or treatment is given to a larger group of people (100–300) to see if it is effective and to further evaluate its safety.

Phase III:
The study drug or treatment is given to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will ensure safe usage.

Phase IV:
These studies are done after the drug or treatment has been marketed. The testing continues to collect information about the effect of the drug or treatment in various populations and determine any side effects from long-term use.


See more information:
Home States of All Active Clinical Center Patients >
Patient Activity and Workforce Distribution >

< Return to the Organization Structure and Programs main page

NIH symbol




The information on this page is archived and provided for reference purposes only.


National Institutes
of Health
  Department of Health
and Human Services